Phase 2 Rare Disease Trial, Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People who are 6 years old or older.
- People who have been diagnosed with primary hyperoxaluria type 1 (PH1) through genetic testing.
- People whose urine tests show oxalate levels outside certain limits, based on at least two 24-hour urine collections.
- People who, if taking vitamin B6, have been on a stable dose for at least 3 months and are willing to keep that dose unchanged throughout the study.
- People (and/or their parent or legal guardian, if under 18) who understand the study and agree to follow all study requirements, including signing a consent form.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People who show signs that oxalate has affected parts of the body outside the kidneys.
- People whose liver blood test results fall outside certain limits.
- People with certain abnormal blood clotting results, unless those results are controlled with medication such as warfarin.
- People who have HIV, or active or chronic hepatitis C.
- People who are pregnant, planning to become pregnant, or breastfeeding.
- People who are not willing to use birth control during the study and for 6 months after the study ends (where applicable).
- People who are unable to limit alcohol intake to no more than approximately 2 drinks per day.
- People who have had alcohol or drug abuse within the past year.
- People who are unable to follow standard treatments for PH1, such as drinking plenty of fluids, taking prescribed medications like potassium citrate, or following dietary advice.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Ling Xiao, MD, PhD, YolTech Therapeutics
Phone: 217-851-5818
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Primary endpoints
Percent Change From Baseline in 24-Hour Urinary Oxalate (BSA-Corrected)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 5 August 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.